207 related articles for article (PubMed ID: 31040211)
1. Hypervariable region 1 and N-linked glycans of hepatitis C regulate virion neutralization by modulating envelope conformations.
Prentoe J; Velázquez-Moctezuma R; Augestad EH; Galli A; Wang R; Law M; Alter H; Bukh J
Proc Natl Acad Sci U S A; 2019 May; 116(20):10039-10047. PubMed ID: 31040211
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.
Velázquez-Moctezuma R; Galli A; Law M; Bukh J; Prentoe J
J Virol; 2019 Feb; 93(4):. PubMed ID: 30487284
[TBL] [Abstract][Full Text] [Related]
3. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
[TBL] [Abstract][Full Text] [Related]
4. Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity.
Prentoe J; Velázquez-Moctezuma R; Foung SK; Law M; Bukh J
Hepatology; 2016 Dec; 64(6):1881-1892. PubMed ID: 27351277
[TBL] [Abstract][Full Text] [Related]
5. Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus.
Prentoe J; Serre SB; Ramirez S; Nicosia A; Gottwein JM; Bukh J
J Virol; 2014 Feb; 88(3):1725-39. PubMed ID: 24257605
[TBL] [Abstract][Full Text] [Related]
6. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
[TBL] [Abstract][Full Text] [Related]
7. Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry.
Prentoe J; Bukh J
Front Immunol; 2018; 9():2146. PubMed ID: 30319614
[TBL] [Abstract][Full Text] [Related]
8. Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A.
Velázquez-Moctezuma R; Law M; Bukh J; Prentoe J
PLoS Pathog; 2017 Feb; 13(2):e1006214. PubMed ID: 28231271
[TBL] [Abstract][Full Text] [Related]
9. Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein.
Vieyres G; Dubuisson J; Patel AH
J Gen Virol; 2011 Mar; 92(Pt 3):494-506. PubMed ID: 21084495
[TBL] [Abstract][Full Text] [Related]
10. Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization.
Prentoe J; Jensen TB; Meuleman P; Serre SB; Scheel TK; Leroux-Roels G; Gottwein JM; Bukh J
J Virol; 2011 Mar; 85(5):2224-34. PubMed ID: 21123377
[TBL] [Abstract][Full Text] [Related]
11. Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies.
Lavie M; Hanoulle X; Dubuisson J
Front Immunol; 2018; 9():910. PubMed ID: 29755477
[TBL] [Abstract][Full Text] [Related]
12. Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice.
Pihl AF; Feng S; Offersgaard A; Alzua GP; Augestad EH; Mathiesen CK; Jensen TB; Krarup H; Law M; Prentoe J; Christensen JP; Bukh J; Gottwein JM
J Hepatol; 2022 May; 76(5):1051-1061. PubMed ID: 34990750
[TBL] [Abstract][Full Text] [Related]
13. Three different functional microdomains in the hepatitis C virus hypervariable region 1 (HVR1) mediate entry and immune evasion.
Guan M; Wang W; Liu X; Tong Y; Liu Y; Ren H; Zhu S; Dubuisson J; Baumert TF; Zhu Y; Peng H; Aurelian L; Zhao P; Qi Z
J Biol Chem; 2012 Oct; 287(42):35631-35645. PubMed ID: 22927442
[TBL] [Abstract][Full Text] [Related]
14. Virus-neutralizing antibodies to hepatitis C virus.
Wahid A; Dubuisson J
J Viral Hepat; 2013 Jun; 20(6):369-76. PubMed ID: 23647953
[TBL] [Abstract][Full Text] [Related]
15. In vitro adaptation and characterization of attenuated hypervariable region 1 swap chimeras of hepatitis C virus.
Olesen CH; Augestad EH; Troise F; Bukh J; Prentoe J
PLoS Pathog; 2021 Jul; 17(7):e1009720. PubMed ID: 34280245
[TBL] [Abstract][Full Text] [Related]
16. Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.
Keck ZY; Girard-Blanc C; Wang W; Lau P; Zuiani A; Rey FA; Krey T; Diamond MS; Foung SK
J Virol; 2016 Jan; 90(6):3112-22. PubMed ID: 26739044
[TBL] [Abstract][Full Text] [Related]
17. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein.
Helle F; Goffard A; Morel V; Duverlie G; McKeating J; Keck ZY; Foung S; Penin F; Dubuisson J; Voisset C
J Virol; 2007 Aug; 81(15):8101-11. PubMed ID: 17522218
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step.
Sabo MC; Luca VC; Prentoe J; Hopcraft SE; Blight KJ; Yi M; Lemon SM; Ball JK; Bukh J; Evans MJ; Fremont DH; Diamond MS
J Virol; 2011 Jul; 85(14):7005-19. PubMed ID: 21543495
[TBL] [Abstract][Full Text] [Related]
19. Global and local envelope protein dynamics of hepatitis C virus determine broad antibody sensitivity.
Augestad EH; Castelli M; Clementi N; Ströh LJ; Krey T; Burioni R; Mancini N; Bukh J; Prentoe J
Sci Adv; 2020 Aug; 6(35):eabb5938. PubMed ID: 32923643
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region.
Alhammad Y; Gu J; Boo I; Harrison D; McCaffrey K; Vietheer PT; Edwards S; Quinn C; Coulibaly F; Poumbourios P; Drummer HE
J Virol; 2015 Dec; 89(24):12245-61. PubMed ID: 26378182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
